Jupiter Neurosciences Announces First Patient Dosed in Phase 2a RESET Trial in Parkinson's Disease and Exploration of Strategic Options to Maximize Shareholder ValueGlobeNewsWire · Oct 6, 2026
Jupiter Neurosciences announces pricing of $2M registered direct offeringThe Fly · Aug 21, 2026
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct OfferingGlobeNewsWire · Aug 21, 2026
Jupiter Neurosciences Stock Surges Friday: What's Driving the Action?Benzinga · Aug 21, 2026
Jupiter Neurosciences, Inc. Announces Reverse Stock SplitGlobeNewsWire · Aug 5, 2026Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | -$3.75 | -$5.06 | Miss |
| May 21, 2026 | -$3.75 | -$4.39 | Miss |
| Apr 3, 2026 | -$5.25 | -$5.61 | Miss |
| Dec 22, 2025 | -$6.00 | -$5.25 | Beat |
| Aug 18, 2025 | -$5.26 | -$5.26 | Beat |
| May 15, 2025 | -$2.26 | -$3.76 | Miss |